Objective To investigate imatinib mesylate and conventional methods in the clinical treatment of patients with chronic myelocytic leukemia. Methods 80 patients with chronic myelocytic leukemia data from February 2013 to February 2015 were ana-lyzed according to the different treatment patients were divided into two groups, the experimental group mesylate Iraq imatinib treatment, the two groups were compared, the control group with conventional chemotherapy treatment. Results 35 cases of com-plete remission, three cases of partial remission, remission rate of 95%, which was significantly higher (27 cases of complete remis-sion, seven cases of partial remission, response rate 85%) (P<0.05);two before treatment, CD3+, CD4+, CD4 +/CD8 + and other T lymphocytes index was not significantly different (P>0.05);the experimental group after treatment CD3+, CD4+, CD4+/CD8+and other T lymphocytes index was significantly higher (P<0.05). Conclusion Patients with chronic myelocytic leukemia using imatinib mesylate desired effect, can improve symptoms and immune function, should be introduced.%目的 探讨甲磺酸伊马替尼和常规方法在慢性粒细胞白血病患者中的临床治疗效果. 方法 随机选取2013年2月-2015年2月收治的80例慢性粒细胞白血病患者资料进行分析,根据不同治疗方案将患者分为两组,实验组采用甲磺酸伊马替尼治疗,对照组采用常规化疗治疗,比较两组疗效. 结果 实验组35例完全缓解,3例部分缓解,缓解率为95%,显著高于对照组(27例完全缓解、7例部分缓解,缓解率为85%)(P<0.05);两组治疗前CD3+、CD4+、CD4+/CD8+等T淋巴细胞指标差异无统计学意义(P>0.05);实验组治疗后CD3+、CD4+、CD4+/CD8+等T淋巴细胞指标显著高于对照组(P<0.05). 结论 慢性粒细胞白血病患者采用甲磺酸伊马替尼治疗效果理想,能够改善患者症状及其免疫功能,值得推广使用.
展开▼
